


www.PDR.net




D

Α

 \bigcirc

Α

R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.



Production Design Supervisor: Adeline Rich Vice President, Regulatory Affairs: Mukesh Mehta, RPh Electronic Publishing Designers: Bryan Dix, Rosalia Sberna, Livio Udina Digital Imaging Coordinator: Michael Labruyere Manager, Professional Data Services: Thomas Fleming, PharmD Director of Client Services: Stephanie Struble

Fulfillment Manager: Louis J. Bolcik

THOMSON Copyright © 2004 and published by Thomson PDR at Montvale, NJ 07645-1742. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. Physicians' Desk Reference®, PDR®, Pocket PDR PDR* PDR* PDR Family Guide to Prescription Drugs*, PDR Family Guide to Women's Health and Prescription Drugs*, and PDR Family Guide to Nutrition and Health* are registered trademarks used herein under license. PDR* for Ophthalmic Medicines, PDR* for Nonprescription Drugs and Dietary Supplements, PDR* Companion Guide, PDR* Pharmacopoeia, PDR* for Herbal Medicines, PDR* for Nutritional Supplements, PDR* Medical Dictionary, PDR* Nurse's Drug Handbook, PDR* Nurse's Dictionary, PDR® Family Guide Encyclopedia of Medical Care, PDR® Family Guide to Natural Medicines and Healing Therapies, PDR® Family Guide to Common Ailments, PDR* Family Guide to Over-the-Counter Drugs, PDR* Family Guide to Nutritional Supplements, and PDR* Electronic Library are trademarks used herein under license.

Promotion Manager: Linda Levine

Editorial Director: Lisette Bralow

Manager, Editorial Services: Bette LaGow

Manager, Concise Data Content: Tammy Chernin, RPh

Officers of Thomson Healthcare,: President and Chief Executive Officer: Richard Noble; Chief Financial Officer: Paul Hilger; Executive Vice President, Clinical Trials: Tom Kelly; Executive Vice President, Medical Education: Jeff MacDonald; Executive Vice President, Clinical Solutions: Jeff Reinl; Executive Vice President, Directory Services; David Duplay; Senior Vice President, Business Development: William Gole; Vice President, Human Resources: Pamela M. Bilash; President, Physician's World: Marty Cearnal

ISBN: 1-56363-471-6

Find authenticated court documents without watermarks at docketalarm.com.

contraceptives and will examine you. The physical examination may be delayed to another time if you request it and the health care provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your health care provider.


HOW TO TAKE THE PILL. See full text of HOW TO TAKE THE PILL which is printed in full in the DETAILED PATIENT LABELING. Keep this and all medication out of the reach of children. Rx only

ave salder graffads.) hernardolaria noRévised: Féb. 7, 2000
Address medical inquiries to: Address medical inquiries to:
WATSON PHARMA, INC.
Medical Information of the second scheme and been references
PO Box 1900
Corona, CA 92878-1149
Mfg. by: Searle & Co. San Juan, PR 00936 for: WATSON PHARMA, INC. a subsidiary of Watson Laboratories, Inc. Corona, CA 92880 Shown in Product Identification Guide, page 339
n, gan anki, <u>espisai 16 anit men i annitit</u> ig bruchan

-opened spec	and the second s	이 집 같이 같이 같이 많이	3,55,070	ore alti	回転 鶴 夏草刀
OXYTRO	TMSS 09 DEFE	na (seoing	ke]⊖ #95	â er îs tr	o contecto,
[ŏks-ē-trōl]	and the seas	deb lates i	din'i ali y	หยายสาย	h juh verva 🖊
[ors-e-trol]		n Satatan	n he con	reads and	t nagarnud
Oxybutynir	n Transderm	ial Syste	m Charles and the second second	la litera	an dia wa
Rx only	a and an an a state	dostantes.	anta a ta	n mente	


DESCRIPTION OXYTROL, oxybutynin transdermal system, is designed to deliver oxybutynin continuously and consistently over a 3to 4-day interval after application to intact skin. **OXYTROL** is available as a 39 cm² system containing 36 mg of oxybutynin. **OXYTROL** has a nominal *in vivo* delivery rate of 3.9 mg oxybutynin per day through skin of average permeability (interindividual variation in skin permeability is approximately 20%).

Oxybutynin is an antispasmodic, anticholinergic agent. Oxybutynin is administered as a racemate of R- and Sisomers. Chemically, oxybutynin is d, I (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate. The empirical formula of oxybutynin is $C_{22}H_{31}NO_3$. Its structural formula is:



Oxybutynin is a white powder with a molecular weight of 357. It is soluble in alcohol, but relatively insoluble in water. Transdermal System Components

OXYTROL is a matrix-type transdermal system composed of three layers as illustrated in Figure 1. below. Layer 1 (Backing Film) is a thin flexible polyester/ethylene-vinyl acetate film that provides the matrix system with occlusivity and physical integrity. and protects the adhesive/drug layer. Layer 2 (Adhesive/Drug Layer) is a cast film of acrylic adhesive containing oxybutynin and triacetin, USP. Layer 3 (Release. Liner) is two overlapped siliconized polyester strips that are peeled off and discarded by the patient prior to applying the matrix system.



(a) A set of the se

CLINICAL PHARMACOLOGY The free base form of oxybutynin is pharmacologically equivalent to oxybutynin hydrochloride. Oxybutynin acts as a competitive antagonist of acetylcholine at postganglionic muscarinic receptors; resulting in relaxation of bladder smooth muscle. In patients with conditions characterized by involuntary detrusor contractions, cystometric studies have demonstrated that oxybutynin increases maximum urinary bladder capacity and increases the volume to first detrusor contraction. Oxybutynin thus decreases urinary urgency and the frequency of both incontinence episodes and voluntary urination.

Oxybutynin is a racemic (50:50) mixture of K- and Sisomers. Antimuscarinic activity resides predominantly in

Information will be superseded by supplements and subsequent editions

Pharmacokinetics Absorption

Oxybutynin is transported across intact skin and into the systemic circulation by passive diffusion across the stratum corneum. The average daily dose of oxybutynin absorbed from the 39 cm² **OXYTROL** system is 3.9 mg. The average (SD) nominal dose, 0.10 (0.02) mg oxybutynin per cm² surface area, was obtained from analysis of 'residual oxybutynin content of systems worn over a continuous 4-day period during 303 separate occasions in 76 healthy volunteers. Following application of the first **OXYTROL** 3.9 mg/ day system, oxybutynin plasma concentration increases for approximately 24 to 48 hours, reaching average maximum concentrations of 3 to 4 ng/mL. Thereafter, steady concentrations are maintained for up to 96 hours. Absorption of oxybutynin is bioequivalent when **OXYTROL** is applied to the abdomen, buttocks, or hip. Average plasma concentrations measured during a randomized, crossover study of the three recommended application sites in 24 healthy men and women are shown in Figure 2.

Figure health tion o	2: Avera ly male a f OXYTR	age plasm nd female OL 3.9 m	a oxybuty voluntee g/day to tl	nin concer rs during s re abdome	trations ((ingle-dose n, buttock	Cp) in 24 applica- and hip
ເວັ້າຊຸ						daana kun
. 1						beerdyd 18 m
-07000 - 1	- 31 1940 H	105 B				case is a la
576.5	71,101	1 th	Territor of		3. 10. Hipore	na dandala
e, ani	to anti-	1	12/19/27	\sim	ganelitig.	$s \approx \sigma_{\lambda} h t$
->r 	A	Assi i di t	and any	S. Sugar	-	she îmale
Ē.	18	stvia, s	No destro	Rh a teor d	11-10-0.0	na glive
						Ceta um
6.00 6.92	4	Inscretz	ang sa	clearto a	Honvra	
						vr to Mos
						des and
	1 10 10	·	In income		11.10 CC	118 0 120
- s (* (*	12					140 120 R7 305 976
						1.0.1

Steady state conditions are reached during the second OXYTROL application. Average steady-state plasma concentrations were 3.1 ng/mL for oxybutynin and 3.8 ng/mL for N-desethyloxybutynin (Figure 3). Table 1. provides, a summary of pharmacokinetic parameters of oxybutynin in healthy volunteers after single and multiple applications of OXYTROL

Figure 3: Average (SEM) steady-state oxybutynin and N-desethyloxybutynin plasma concentrations (Cp) measured in 13 healthy volunteers following the second transdermal system application in a multiple-dose, randomized, crossover study.





Table 1: Mean (SD) oxybutynin pharmacokinetic parameters from single and multiple dose studies in healthy men and women volunteers after application of OXYTROL on the abdomen.

Dosing	Oxybutynin							
	C _{max} (SD) (ng/mL)	T _{max} ¹ (hr)	C _{avg} (SD) (ng/mL)	AUC (SD) (ng/mLxh)				
Single	3.0 (0.8)	48	na <u>vidan</u> e de tra	245 (59) ²				
	3.4 (1,1)	36	<u>ب میں جد میں اور اور اور اور اور اور اور اور اور اور</u>	279 (99) ²				
Multiple	6.6 (2.4)	70 10 7000	4.2 (1.1)	408 (108) ³				
an an the sa	4.2 (1.0)	28	3.1 (0.7)	259 (57) ⁴				

 1 T_{max} given as median . So the second state of the sec

Distribution The volume of distributed in body tissues following Systemic absorption. The volume of distribution was estimated to be 193 L after intravenous administration of 5 mg oxybutynin chloride.

Actionshift is metabolized primarily by the cytochrome P450 enzyme systems, particularly CYP3A4, found mostly in the liver and gut wall. Metabolites include phenylcyclohexylglycolic acid, which is pharmacologically inactive, and N-desethyloxybutynin, which is pharmacologically active. ethyl metabolite compared to oxybutynin (see Figure 4). The plasma concentration AUC ratio of N-desethyl metabolite to parent compound following a single 5 mg oral dose of oxybutynin chloride was 11.9.1. The following a single 5 mg oral dose of first-pass gastrointestinal and hepatic metabolism, reducing the formation of the N-desethyl metabolite (see Figure 4). Only small amounts of CYP3A4 are found in skin, limiting pre-systemic metabolism during transformal absorption. The resulting plasma concentration AUC ratio of Ndesethyl metabolite to parent compound following multiple OXYTROL applications was 1.3:1.



WHEN TO START THE FIRST PACK OF PLLS

Following intravenous administration, the elimination halflife of oxybutynin'is approximately 2 hours. Following removal of OXYTHOL: plasma'eoncentrations of Oxybutynin and N-desethyloxybutynin decline with an apparent halflife of approximately 7 to 8 hours.

Oxybitynin is extensively metabolized by the liver, with less than 0.1% of the administered dose excreted unchanged in the urine: Also, less than 0.1% of the administered dose is excreted as the metabolite N-desethyloxybutynin.¹⁶ Jord Special Populations

Special Populations Geriatric: The pharmacokinetics of oxybitynin and Ndesethyloxybutynin were similar in all patients studied. Pediatric: The pharmacokinetics of oxybutynin and Ndesethyloxybutynin were not evaluated in individials younger than 18 years of age. See PRECAUTIONS: Pediatric Use! Gender. There were no significant differences in the phar-

Gender: There were no significant differences in the pharmacokinetics of oxybutynin in healthy male and female volunteers following application of **OXYTROL**. Race: Available data suggest that there are no significant

Race: Available data suggest that there are no significant differences in the pharmacokinetics of oxybutynin based on race in healthy volunteers following administration of **OXYTROL**. Japanese volunteers demonstrated a somewhat lower metabolism of oxybutynin to N-desethyloxybutynin compared to Caucasian volunteers. Use data with the use of Renal Insufficiency: There is no experience with the use of

OXYTROL in patients with renal insufficiency. Hepatic Insufficiency: There is no experience with the use of OXYTROL in patients with hepatic insufficiency. Drug Drug Interactions: See **PRECAUTIONS!** Drug In-

Drug-Drug Interactions: See PRECAUTIONS: Drug) In teractions: lead areas to a spale and not focal time with hards. Adhesion areas leading accorded to a standard period. Jug

Adhesion was periodically evaluated during the Phase 3 studies. Of the 4,746 **OXYTROL** evaluations in the Phase 3 trials, 20 (0.4%) were observed at clinic visits to have become completely detached and 35 (0.7%) became partially detached during routine clinic use. Similar to the pharma-cokinetic studies, > 98% of the systems evaluated in the Phase 3 studies were assessed as being \geq 75% attached and thus would be expected to perform as anticipated.

The efficacy and safety of OXYTROL were evaluated in patients with urge urinary incontinence in two Phase 3 controlled studies and one open-label extension. Study 1 was a Phase 3, placebo controlled study, comparing the safety and efficacy of OXYTROL at dose levels of 1.3, 2.6, and 3.9 mg/ day to placebo in 520 patients. Open-label treatment was available for patients completing the study. Study 2 was a Phase 3 study, comparing the safety and efficacy of OXYTROL 3.9 mg/day versus active and placebo controls in 361 patients.

Study 1 was a randomized, double-blind, placebo-controlled, parallel group study of three dose levels of OXTIROL conducted in 520 patients. The 12-week double-blind treatment included OXYTROL doses of 1.3, 2.6, and 3.9 mg/day with matching placebo. An open-label, dose titration treatment extension allowed continued treatment for up to an additional 40 weeks for patients completing the double-blind period. The majority of patients were Caucasian (91%) and female (92%) with a mean age of 61 years (range, 20 to 88 years). Entry criteria required that patients have urge or mixed incontinence (with a predominance of urge), urge in continence episodes of \approx 10 per week, and \geq 8 micturitions per day. The patient's medical history and a urinary diary during the treatment free baseline period confirmed the diagnosis of urge incontinence. Approximately 80% of patients had no prior pharmacological treatment for incontinence

Find authenticated court documents without watermarks at docketalarm.com

live deadlient groups are summarized in Table 2

Table 2: Mean and median change from baseline to end of treatment (Week 12 or last observation carried forward) in incontinence episodes, urinary frequency, and urinary void volume in patients treated with OXYTROL 3.9 mg/day or placebo for 12 weeks (Study 1).

Parameter		ebo 127)	OXYTROL 3.9 mg/day (N=120)			
	Mean (SD)		Mean (SD)	Median		
Weekly Incont	inence Epi	sodes	2			
Baseline	37.7 (24.0)	30	34.3 (18.2)	31		
Reduction	19.2 (21.4)	15	21.0 (17.1)	19		
p value vs. placebo			0.0265*			
Daily Urinary	Frequency	7	1			
Baseline	12.3 (3.5)	11	11.8 (3.1)	11 · · · 11		
Reduction	1.6 (3.0)	1	2.2 (2.5)	2		
p value vs. placebo	25 		0.0313*			
Urinary Void	Volume (m	L)	6 0- 9 0			
Baseline	175.9 (69.5)	166.5 ö	171.6 (65.1)	168		
Increase	10.5 (56.9)	5.5 ^{.3}	31.6 (65.6)	26		
p value vs. placebo	nin Konsection Konsection	in the second	0.00)09**		

*Comparison significant if p < 0.05

**Comparison significant if $p \le 0.0167$

Study 2 was a randomized, double-blind, double-dummy study of OXYTROL 3.9 mg/day versus active and placebo controls conducted in 361 patients. The 12-week doubleblind treatment included an OXYTROL dose of 3.9 mg/day, an active comparator, and placebo. The majority of patients were Caucasian (95%) and female (93%) with a mean age of 64 years (range, 18 to 89 years). Entry criteria required that all patients have urge or mixed incontinence (with a predominance of urge) and had achieved a beneficial response from the anticholinergic treatment they were using at the time of study entry. The average duration of prior pharmacological treatment was greater than 2 years. The patient's medical history and a urinary diary during the treatmentfree baseline period confirmed the diagnosis of urge incontinence. Reductions in daily incontinence episodes, urinary frequency, and urinary void volume between placebo and active treatment groups are summarized in Table 3.

Table 3: Mean and median change from baseline to end of treatment (Week 12 or last observation carried forward) in incontinence episodes, urinary frequency, and urinary void volume in patients treated with OXYTROL 3.9 mg/day or 17 placebo for 12 weeks (Study 2).

Parameter	Plac (N=	ebo 117)	OXYTROL 3.9 mg/da (N=121)			
n an a' a' ann a' The sail ann a' a' Màiste	Mean (SD)	Median	Mean (SD)	Median		
Daily Incontin	ence Episo	des	an an an De Sueder	n an		
Baseline	5.0 (3.2)	4	4.7 (2.9)			
Reduction	2.1 (3.0)	2	2.9 (3.0)	3		
p value vs. placebo	1999 - 2019 - 10 1999 - 10 - 20 1999 - 10 - 20	nos do sein 12 - Inno Co 1459 Constant	0.0137*			
Daily Urinary	Frequency	·	a deservationes des			
Baseline	12.3 (3.3)	112	12.4 (2.9)	12		
Reduction	1.4 (2.7)	1 ×1	1.9 (2.7)	2		
p value vs. placebo	an cana -	lene prot Lett Runget		010*		
Urinary Void	Volume (m	L) shin, in	respired angle	er anges av		
Baseline and other state			164.8 (62.3)	5 (1 60) 10 (1703)		

RM

DOCKE.

p value vs.		a tariha da ana ana ana ana ana ana ana ana ana
p value vs. placebo	·	0.0010*
*Comparison	significant if p < 0.05	· · · · · ·

INDICATIONS AND USAGE

OXYTROL is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

CONTRAINDICATIONS

OXYTROL is contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow angle glau-coma and in patients who are at risk for these conditions. OXYTROL is also contraindicated in patients who have demonstrated hypersensitivity to oxybutynin or other components of the product.

PRECAUTIONS

General

OXYTROL should be used with caution in patients with hepatic or renal impairment.

Urinary Retention: OXYTROL should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of urinary retention (see CONTRAINDICATIONS).

Gastrointestinal Disorders: OXYTROL should be adminis-tered with caution to patients with gastrointestinal obstruc-tive disorders because of the risk of gastric retention (see CONTRAINDICATIONS).

OXYTROL, like other anticholinergic drugs, may decrease gastrointestinal motility and should be used with caution in patients with conditions such as ulcerative colitis, intestinal atony, and myasthenia gravis. OXYTROL should be used with caution in patients who have gastroesophageal reflux and/or who are concurrently taking drugs (such as bisphosphonates) that can cause or exacerbate esophagitis. Information for Patients

Patients should be informed that heat prostration (fever and heat stroke due to decreased sweating) can occur when anticholinergics such as oxybutynin are used in a hot environment. Because anticholinergic agents such as oxybutynin may produce drowsiness (somnolence) or blurred vision, patients should be advised to exercise caution. Patients should be informed that alcohol may enhance the drowsiness caused by anticholinergic agents such as oxybutynin.

OXYTROL should be applied to dry, intact skin on the abdomen, hip, or buttock. A new application site should be se-lected with each new system to avoid re-application to the same site within 7 days. Details on use of the system are explained in the patient information leaflet that should be dispensed with the product.

Drug Interactions

The concomitant use of oxybutynin with other anticholinergic drugs or with other agents that produce dry mouth, constipation, somnolence, and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. Pharma-cokinetic studies have not been performed with patients concomitantly receiving cytochrome P450 enzyme inhibitors, such as antimytotic agents (e.g. ketoconazole, itraconazole, and miconazole) or macrolide antibiotics (e.g. erythromycin and clarithromycin). No specific drug-drug interaction studies have been performed with OXYTROL. Carcinogenesis, Mutagenesis, Impairment of Fertility

A 24-month study in rats at dosages of oxybutynin chloride of 20, 80 and 160 mg/kg showed no evidence of carcinogenicity. These doses are approximately 6, 25 and 50 times the maximum exposure in humans taking an oral dose based on body surface area.

Oxybutynin chloride showed no increase of mutagenic activity when tested in Schizosaccharomyces pompholiciformis, Saccharomyces cerevisiae, and Salmonella typhimurium test systems. Reproduction studies with oxybutynin chloride in the mouse, rat, hamster, and rabbit showed no definite evidence of impaired fertility.

Pregnancy: Teratogenic Effects Pregnancy Category B

Reproduction studies with oxybutynin chloride in the mouse, rat, hamster, and rabbit showed no definite evidence of impaired fertility or harm to the animal fetus. Subcutaneous administration to rats at doses up to 25 mg/kg (approximately 50 times the human exposure based on surface area) and to rabbits at doses up to 0.4 mg/kg (approximately 1 times the human exposure) revealed no evidence of harm to the fetus due to oxybutynin chloride. The safety of OXYTROL administration to women who are or who may become pregnant has not been established. Therefore, OXYTROL should not be given to pregnant women unless, in the judgment of the physician, the probable clinical benefits outweigh the possible hazards. Nursing Mothers

It is not known whether oxybutynin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when OXYTROL is administered to a nursing woman. usitenzora b

Geriatric Use

Of the total number of patients in the clinical studies of OXYTROL, 49% were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in response between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see CLINICAL PHARMA-COLOGY, Pharmacokinetics, Special Populations: Geriatríc).

ADVERSE REACTIONS

The safety of **OXYTROL** was evaluated in a total of 417 pa-tients who participated in two Phase 3 clinical efficacy and safety studies and an open-label extension. Additional safety information was collected in Phase 1 and Phase 2 tri-als. In the two pivotal studies, a total of 246 patients re-ceived OXYTROL during the 12-week treatment periods. A total of 411 patients entered the open-label extension and of those, 65 patients and 52 patients received OXYTROL for at least 24 weeks and at least 36 weeks, respectively. No deaths were reported during treatment. No serious adverse events related to treatment were reported.

Adverse events reported in the pivotal trials are summarized in Tables 4 and 5 below, $\eta_{\rm CAV} = (\pi b \sqrt{n}, 0, 1, 1) H^2$

Table 4: Number (%) of adverse events occurring in $\geq 2\%$ of OXYTROL-treated patients and greater in OXYTROL group than in placebo group (Study 1).

Adverse Event*	Placebo (N=132) N%	OXYTROL (3.9 mğ/day) (N=125) N
Application, site pruritus	8 6.1%	1999 97 97 97 97 97 97 97 97 97 97 97 97
Dry mouth	11 8.3%	9.6%
Application site erythema	3 2.3%	7 5.6%
Application site vesicles	0 0.0%	4 3.2%
Diarrhea	3 2.3%	4 3.2%
Dysuria	0 0.0%	3. 2.4%

*includes adverse events judged by the investigator as possibly, probably or definitely treatment-related.

Table 5: Number (%) of adverse events occurring in $\geq 2\%$ of OXYTROL-treated patients and greater in OXYTROL group than in placebo group (Study 2). 98. F 201.2

Adverse Event*	(N=	æbo 117) %	OXYTROL (3.9 mg/day (N=121) N %					
Application site pruritus	5 - 105 5 - 5	4.3%	107. (11) 111 - 117	14.0%				
Application site erythema	2	1.7%	10	8.3%				
Dry mouth	2	1.7%	1.35000 5 5554	4.1%				
Constipation	0.	0.0%	4	3.3%				
Application site rash	1	0.9%	4	3.3%				
Application site macules	0	0.0%	3	2.5%				
Abnormal vision	0	0.0%	3	2.5%				

*includes adverse events judged by the investigator as possibly, probably or definitely treatment-related

Other adverse events reported by > 1% of OXYTROL-treated patients, and judged by the investigator to be possibly, probably or definitely related to treatment include: abdominal pain, nausea, flatulence, fatigue, somnolence, headache, flushing, rash, application site burning and back pain. Most treatment-related adverse events were described as mild or moderate in intensity. Severe application site reac-tions were reported by 6.4% of **OXYTROL**-treated patients in Study 1 and by 5.0% of OXYTROL-treated patients in Study

Treatment-related adverse events that resulted in discon-tinuation were reported by 11.2% of **OXYTROL**-treated pa-tients in Study 1 and 10.7% of **OXYTROL**-treated patients in Study 2. Most of these were secondary to application site reaction. In the two pivotal studies, no patient discontinued OXYTROL treatment due to dry mouth In the open-label extension, the most common treatmentrelated adverse events were: application site pruritus, application site erythema and dry mouth. se; doldar anivos

Continued on next page

Consult 2004 PDR® supplements and future editions for revisions

Find authenticated court documents without watermarks at docketalarm.com.

Coxytrol Cont. A state was to the state was the state of	2.5					entage cont	inuing use a	at the end of	the first ye	ar. United
OVERDOSAGE					c. Satistics		mai i			<u></u>
Plasma concentration of oxybutynin declines within 1 to 2	1.	3,0	3							of Women
hours after removal of transdermal system(s). Patients	1.5		la su companya ang sa		Pregna					nuing Use at
should be monitored until symptoms resolve. Overdosage	1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 - 1997 -		ेखेरी न दक्षि	N. A. Ashiri	delaa dafati i	0102 7.16	neu ses vi	นธาตุราชสหมภ	1991 - 1991 - 19 1	ne Year ^a na ana
with oxybutynin has been associated with anticholinergic	Method				Typica	1 11001	Por	ect use ²	787120291 (ARR) - 129 - 41-1	nako en anarazz
effects including CNS excitation, flushing, fever, dehydra-	(1)		1. 1. 1. Mars 2. 2	n an				(3)		(4)
tion, cardiac arrhythmia, vomiting, and urinary retention.			1.000			0	<u> </u>	(0)		(
Ingestion of 100 mg oral oxybutynin chloride in association	Chance ⁴	-10.2628	alan (mit)	al population a	85	1 180-180-18 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1212/2011 - 1	5	okanasin karala YangaZara	i i i i i i i i i i i i i i i i i i i
with alcohol has been reported in a 13 year old boy who ex-	Spermicides	5 - 1 - 2 - 2 M	Kinaldi (S	e l'é eupere	26	a na sa	antanyinali siye, sari	6		40
perienced memory loss, and in a 34 year old woman who developed stupor, followed by disorientation and agitation	Periodic abs	tinence	and the second	1	(Hupper in 25)) paikok	s i saaki		1259W	63
on awakening, dilated pupils, dry skin, cardiac arrhythmia,	Calendar			NORANGE	0.27065	Las zot 1		9	(523)	
and retention of urine. Both patients recovered fully with	Ovulation	method	allea i bhai	e da da cara d	a enversionen			.3		
symptomatic treatment.	Sympto-th		oo aa la saada ahaa ahaa ahaa ahaa ahaa ahaa ah	si artoida e	Andrews and the second s			2 sede	elgã ascon	Nacher 19.00
	Post-ovula		in the in	da un di di di di das se di di di d	n anna chuise Na Aiste an aiste	، محبوبة والمشهور و		1	interes a series of	
DOSAGE AND ADMINISTRATION	Withdrawal		ા નાંગ્રે તેવેલાં	der in the der	19	i (N	i de la composición d Composición de la composición de la comp	4		revesso
OXYTROL should be applied to dry, intact skin on the abdo-	Cap' Parous wo	- El Menne		Welling Street			لأفيد بالكتب		(1) des (1)	
men, hip, or buttock. A new application site should be se-			5 - 1 - 1 - 1 1	Same	40	1	2	6	4.01	42
lected with each new system to avoid re-application to the		us women		. POR	20		i de la casa A de trata	9		56
same site within 7 days.	Sponge Parous we	mon		8208	40	manufacture and the second	نىلىدىدا ئىيىنى 1. ئىلىرىت بىلىيىن	N	i eriteti Azərbaycan	40
The dose of OXYTROL is one 3.9 mg/day system applied				ioar of Muod			· · · · 4	0		56 batavia
twice weekly (every 3 to 4 days).	paro	na women	する(69 烏田賢二	ଯ୍ୟତ୍ର ବିଶ୍ୱାର୍ଥ୍ୟରା ଅନ୍ୟର୍ଥର	S 19 98 1 1 10					00

The twice weekly (every 3 to 4 days). OXYTROL 3.9 mg/day (oxybutynin transdermal system). Each 39 cm² system imprinted with OXYTROL 3.9 mg/day contains 36 mg oxybutynin for nominal delivery of 3.9 mg oxybutynin per day when dosed in a twice weekly regimen. NDC 52544-920-08 Patient Calendar Box of 8 Systems

Storage Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Protect from moisture and humidity. Do not store outside the sealed bouch. Apply immediately after removal from the protective pouch. Discard used OXYTROL in household trash in a manner that prevents accidental application or ingestion by children, pets, or others.

WATSON Pharma, Inc. A Subsidiary of Watson Pharmaceuticals, Inc. Corona, CA 92880 USA DATE OF ISSUANCE: FEBRUARY 2003

U.S. Patent Nos. 5,601,839 and 5,834,010 Shown in Product Identification Guide, page 339

TRI-NORINYL@-28

sym ĐØ OX mer lect

(norethindrone and ethinyl estradiol) B only


Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases. ORAL CONTRACEPTIVE AGENTS

and sale

DESCRIPTION

Tri-NorinyI-28 provides a continuous oral contraceptive regimen of 7 blue tablets, 9 yellow-green tablets, 5 more blue tablets, and then 7 orange tablets. Each blue tablet contains norethindrone 0.5 mg and ethinyl estradiol 0.035 mg, each yellow-green tablet contains norethindrone 1 mg and ethinyl estradiol 0.035 mg, and each orange tablet contains inert ingredients.

Norethindrone is a potent progestational agent with the chemical name 17-Hydroxy-19-nor-17α-pregn-4-en-20-yn-3one. Ethinyl estradiol is an estrogen with the chemical name 19-Nor-17 α -pregna-1,3,5(10)-trien-20-yne-3,17-diol. Their structural formulae follow:



The yellow-green TRI-NORINYL tablets contain the following inactive ingredients: D&C Green No. 5, D&C Yellow No. 10, lactose, magnesium stearate, povidone, and starch. The blue TRI-NORINYL tablets contain the following inactive ingredients: FD&C Blue No. 1, lactose, magnesium

stearate, povidone, and starch. The inactive grange tablets in the 28-day regimen contain the following inactive ingredients: FD&C Yellow No. 6, lactose, magnesium stearate, povidone, and starch.

CLINICAL PHARMACOLOGY

Combination oral contraceptives act by suppression of gona dotrophins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which may reduce the likelihood of implantation).

monte and euheomiant

Temparing women and the second h li chɗ 56 5 3 61 $\tilde{71}^{\rm physical scale}$ Progestin only as a compared to a construction of the second second 0.5 Combined a rain of 5 we have at a standard transition of the standard stand 0.1 Reduction IUD 1.5 2.0 81 Copper T 380A di supervisione mello mili. ICHOIX 0.8 0.6 78 cdobala LNg 20 (1) man and the state of 0.1 0.1 81 70 0.3 0.3 0.05 0.05 88 alung confine dar here dan Female sterilization and the distribution of the second distribution of the 0.5 0.5 100 ' कुई (ई) (हि

Emergency Contraceptive Pills. Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%

0.15

Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception.¹⁰

Source: Trussell J. Contraceptive Efficacy Table from Hatcher R.A., Trussell J. Stewart F, Cates W, Stewart GK, Kowal D, Guest F, in Contraceptive Technology: Seventeenth Revised Edition. New York, NY: Irvington Publishers, 1998.

Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any

- other reason. Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year.
- The percentage becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contra-ception altogether. Foams, creams, gels, vaginal suppositories, and vaginal film.
- Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases.
- Without spermicides.

R

- The treatment schedule is one dose within 72 hours after unprotected intercourse and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral (1 dose is 2 white pills). Aleese (1 dose is 5 pink pills), Nordette or Levlen (1 dose is 2 light-orange pills), Lo/Ovral (1 dose is 4 white pills), Triphasil or Tri-Levlen (1 dose is 4 yellow pills).
- ¹⁰ However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches six months of age. a constant of the second second

annorse do las

INDICATIONS AND USAGE

Line and the state of the second s

Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.

Oral contraceptive products such as Norinyl, which contain 50 mcg of estrogen, should not be used unless medically indicated.

Oral contraceptives are highly effective. Table 1 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. [See table 1 above]

CONTRAINDICATIONS

Oral contraceptives should not be used in women who have the following conditions:

- Thrombophlebitis or thromboembolic disorders
- A past history of deep vein thrombophlebitis or thromboembolic disorders
- Cerebral vascular or coronary artery disease
- Known or suspected carcinoma of the breast · Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia
- Undiagnosed abnormal genital bleeding
- Cholestatic jaundice of pregnancy or jaundice with prior
- pill use
- Hepatic adenomas, carcinomas or benign liver tumors
- Known or suspected pregnancy

Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. This risk increases with age and with heavy smoking (15 or more cigarettes per day) and is quite marked in women over 35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.

56 vilonta

100

The use of oral contraceptives is associated with increased risks of several serious conditions including myocardial infarction, thromboembolism, stroke, hepatic neoplasia, and gallbladder disease, although the risk of serious morbidity your mortality is very small in healthy women without under-lying risk factors. The risk of morbidity and mortality in-creases significantly in the presence of other underlying risk factors such as hypertension, hyperlipidemias, hypercholes-terolemia, obesity and diabetes.²⁻⁵

miliar with the following information relating to these risks. The information contained in this package insert is principally based on studies carried out in patients who used oral contraceptives with higher formulations of both estrogens and progestogens than those in common use today.⁶⁻¹¹ The effect of long-term use of the oral contraceptives with lower formulations of both estrogens and progestogens remains to be determined.

Throughout this labeling, epidemiological studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease. Relative risk, the ratio of the incidence of a disease among oral contraceptive

Find authenticated court documents without watermarks at docketalarm.com.

ยารถแหว่งรายประการรายการและรังหน่อย ออกแรมีมีเสอุณี da a complete states in exercit

0.10

WARNINGS